# US 2018/0021455 A1 · Receptor-targeted nanoparticles for enhanced transcytosis mediated drug delivery

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0021455 A1
- Document ID: US20180021455A1
- Status: Published application
- Kind: A1
- Application number: 15/692,116
- Filed: 2017-08-31
- Published: 2018-01-25
- Earliest claimed: 2006-11-20
- Assignees: The Brigham and Women's Hospital, Inc.; Massachusetts Institute of Technology
- Applicants: The Brigham and Women's Hospital, Inc.; Massachusetts Institute of Technology
- Inventors: Eric M. Pridgen; Frank Alexis; Omid C. Farokhzad; Robert S. Langer; Richard S. Blumberg
- Web page: https://patentgrep.com/patent/US20180021455A1

## CPC

- A61K 47/6931: {the material constituting the nanoparticle being a polymer}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/50: Microcapsules {having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals (A61K9/2081 takes precedence; particles with a single coating comprising drug A61K9/167)}
- A61K 9/5089: {Processes}
- A61K 38/28: Insulins
- A61K 47/68: the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K 47/6849: {the antibody targeting a receptor, a cell surface antigen or a cell surface determinant}
- A61K 47/6929: {the form being a nanoparticle, e.g. an immuno-nanoparticle}
- A61K 47/6935: {the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol}
- A61P 5/38: of the suprarenal hormones
- C07K 16/283: {against Fc-receptors, e.g. CD16, CD32, CD64 (CD23 C07K16/2851)}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/52: Constant or Fc region; Isotype
- C07K 2317/524: CH2 domain
- C07K 2317/526: CH3 domain
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Receptor-targeted nanoparticles (R-NPs) are provided for selective transport into and through targeted tissues of therapeutic, prophylactic and diagnostic agents. R-NPs can include polymeric particle, lipid particles, inorganic particles, or a combination thereof with a targeting moiety selective for binding to a receptor on the cells where the agent is to be delivered, where the receptor mediates transcytosis of the nanoparticle into and through the cells. In a preferred embodiment, the targeting moiety is the neonatal Fc receptor. Examples demonstrate Fc-targeted nanoparticles which are actively transported across the intestinal epithelium, providing a route for the oral delivery of nanoparticle encapsulated active agents including peptides such as insulin.

## Claims

### Claim 1

A nanoparticle formulation for transport of agents through tissue, tissue barriers, and tissue linings comprising an effective amount of polymeric nanoparticles comprising
an outer surface comprising a blend of a first amphiphilic block co-polymer comprising a hydrophobic block and a hydrophilic block with a targeting moiety conjugated thereto, and a second polymer selected from an amphiphilic block co-polymer and a hydrophobic polymer, wherein the targeting moiety is absent from the second polymer; and
a core comprising a therapeutic, prophylactic, or diagnostic agent,
wherein the targeting moiety is present on the exterior surface of the nanoparticles and can bind to a receptor on the surface of the cells in the tissue to effect transcytosis of the nanoparticles into and through the cells.

### Claim 2 (depends on 1)

The nanoparticle formulation of claim 1 for delivery into and through heart, skeletal muscle, or adipose tissue, wherein the receptors are selected from the group consisting of gp60 and ligands for FcRn.

### Claim 3 (depends on 1)

The nanoparticle formulation of claim 1 for delivery into and through testis tissue, wherein the receptors are selected from the group consisting of chorionic gonadotropin receptor, Insulin receptor and insulin-like growth factor receptor, FcRn, and Transferrin receptor.

### Claim 4 (depends on 1)

The nanoparticle formulation of claim 1 for delivery into and through brain tissue, wherein the receptors are selected from the group consisting of insulin receptor; insulin-like growth factor receptor; LDL receptor-related proteins 1 and 2 (LRP1 and LRP2); LDL receptor; Diptheria toxin receptor; Transferrin; Receptor for advanced glycation end products (RAGE); Scavenger receptor (SR); and ligands for FcRn.

### Claim 5 (depends on 1)

The nanoparticle formulation of claim 1 for delivery into and through intestinal tissue, wherein the receptors are selected from the group consisting of receptors for M cells; Terminal galactose (ricin B receptor); aminopeptidase N; pIgA receptor; FcRn; CD23 (for IgE); and Cubulin/Megalin (vitamin B12).

### Claim 6 (depends on 1)

The nanoparticle formulation of claim 1 for delivery into and through liver tissue, wherein the receptor is pIgA or FcRn.

### Claim 7 (depends on 1)

The nanoparticle formulation of claim 1 for delivery into and through kidney tissue, wherein the receptors are selected from the group consisting of pIgA, Megalin, FcRn, and Terminal galactose (ricin B receptor).

### Claim 8 (depends on 1)

The nanoparticle formulation of claim 1 for delivery into and through placental tissue, wherein the receptors are selected from the group consisting of aminopeptidase N, pIgA, FcRn, Transferrin, and Megalin.

### Claim 9 (depends on 1)

The nanoparticle formulation of claim 1 for delivery into and through lung tissue, wherein the receptors are selected from the group consisting of ligands for FcRn; Transferrin; Terminal galactose (ricin B receptor); pIgA; FcRn; CD23 (for IgE); and gp60.

### Claim 10 (depends on 1)

The nanoparticle formulation of claim 1 for delivery into and through mammary gland tissue, wherein the receptors are selected from the group consisting of gp60; aminopeptidase N; pIgA; FcRn; and Transferrin.

### Claim 11 (depends on 1)

The nanoparticle formulation of claim 1 for delivery into and through thyroid tissue, wherein the receptor is gp60 and Megalin.

### Claim 12 (depends on 1)

The nanoparticle formulation of claim 1 for delivery into and through genitourinary tract tissue, wherein the receptors are selected from the group consisting of pIgA, Transferrin, Megalin; gp340; FcRn; and lutropin receptor.

### Claim 13 (depends on 1)

The nanoparticle formulation of claim 1 wherein the receptors are ligands for FcRn.

### Claim 14 (depends on 1)

The nanoparticle formulation of claim 1, wherein the targeting moieties are selected from the group consisting of proteins, peptides, amino acids, lipid, carbohydrate, nucleic acid, small molecules, and combinations thereof.

### Claim 15 (depends on 13)

The nanoparticle formulation of claim 13, wherein the targeting moieties are antibodies or fragments thereof binding to FcRn.

### Claim 16 (depends on 13)

The nanoparticle formulation of claim 13, wherein the FcRn receptor targeting moieties are IgG (all isotypes) Fc fragments engineered to have altered binding to the FcRn or reduce immunogenicity.

### Claim 17 (depends on 16)

The nanoparticle formulation of claim 16, wherein the IgG Fc has mutations in the CH2 and CH3 domains.

### Claim 18 (depends on 13)

The nanoparticle formulation of claim 13, wherein the FcRn targeting moieties are IgG (all isotypes) Fc fragments engineered with distinct mutations, deletions or additions of amino acids, and are 95%, 90% or 85% homologous to the Fc fragment.

### Claim 19 (depends on 16)

The nanoparticle formulation of claim 16, wherein IgG (all isotypes) Fc fragments have one or more of the mutations in the CH2 and CH3 domain selected from the group consisting of T250Q/M428L, M252Y/S254T/T256E+H433K/N434F, E233P/L234V/L235A/?G236+A327G/A330S/P331S, K322A, and L235E+E318A/K320A/K322A.

### Claim 20 (depends on 1)

The nanoparticle formulation of claim 1 comprising two or more types of receptor binding moieties.

### Claim 21 (depends on 1)

The nanoparticle formulation of claim 1, wherein the nanoparticle comprises one or more targeting moieties targeting a specific organ, tissue, cell type, or subcellular compartment.

### Claim 22 (depends on 1)

The nanoparticle formulation of claim 1 comprising a targeting moiety binding to a target that does not mediate transcytosis into the cell.

### Claim 23

(canceled)

### Claim 24 (depends on 1)

The nanoparticle formulation of claim 1, wherein the targeting moieties are present in a density greater than about 1 mg targeting moiety to about 500 mg particle or at least 10 moieties per square micron.

### Claim 25 (depends on 1)

The nanoparticle formulation of claim 1, wherein the targeting moieties are present on the surface of the nanoparticles in a density greater than about 1,000 moieties per square micron.

### Claim at position 26

26-27. (canceled)

### Claim 28 (depends on 1)

The nanoparticle formulation of claim 1 wherein a targeting moiety that effects transcytosis of the nanoparticles is released from the nanoparticle surface after the nanoparticle crosses the tissue, tissue barrier, or tissue lining, optionally by a change in pH, change in temperature, enzymatic degradation, change in flow shear rate, change in magnetic field, change in electric field, or change in ionic strength.

### Claim 29 (depends on 1)

The nanoparticle formulation of claim 1, wherein the therapeutic, prophylactic or diagnostic agent is released by a change in pH, change in temperature, enzymatic degradation, change in flow shear rate, change in magnetic field, change in electric field, or change in ionic strength.

### Claim at position 29

30-32. (canceled)

### Claim 33 (depends on 1)

The nanoparticle formulation of claim 1, wherein the hydrophobic block comprises a polymer selected from the group consisting of polyhydroxyacids, polyhydroxyalkanoates, polycaprolactones, poly(orthoesters), polyanhydrides; poly(phosphazenes), poly(lactide-co-caprolactones), polycarbonates, polyesteramides, polyesters, poly(dioxanones), poly(alkylene alkylates), polyethers, polyurethanes, polyetheresters, polyacetals, polycyanoacrylates, polyacrylates, polymethylmethacrylates, polysiloxanes, polyketals, polyphosphates, polyhydroxyvalerates, polyalkylene oxalates, polyalkylene succinates, poly(maleic acids), and copolymers thereof.

### Claim 34 (depends on 33)

The nanoparticle formulation of claim 33, wherein the hydrophobic block comprises a polymer selected from the group consisting of poly(lactic acid), poly(glycolic acid), and poly(lactic acid-co-glycolic acids).

### Claim 35 (depends on 1)

The nanoparticle formulation of claim 1, wherein the hydrophilic block comprises a polymer selected from the group consisting of cellulosic polymers, polypeptides, poly(amino acids), polyalkylene glycols, polyalkylene oxides, poly(hydroxy acids); poly(vinyl alcohols), and copolymers thereof.

### Claim 36

(canceled)

### Claim 37 (depends on 1)

The nanoparticle formulation of claim 1 comprising a lipid disposed between the outer surface and the core of the nanoparticles.

### Claim 38 (depends on 1)

The nanoparticle formulation of claim 1, wherein the targeting moieties are adsorbed, absorbed, conjugated, complexed, bound, or assembled into the nanoparticle or a component thereof prior to or after formation of the nanoparticles.

### Claim 39 (depends on 1)

The nanoparticle formulation of claim 1 comprising a polyalkylene oxide surface on the nanoparticles.

### Claim 40 (depends on 1)

The nanoparticle formulation of claim 1 wherein the nanoparticles have a diameter of between 3 and 500 nm, preferably between 10 and 150 nm.

### Claim at position 38

41-82. (canceled)
